21900-41-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-methylbenzoyl chloride is used as a reagent for the synthesis of complex organic molecules in the pharmaceutical industry. Its ability to undergo reactions such as acylation and Friedel-Crafts acylation makes it an important compound in the development of new drugs and medicinal agents.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-2-methylbenzoyl chloride is utilized as a key intermediate in the production of various agrochemicals. Its reactivity and functional group compatibility contribute to the creation of effective pesticides and other agricultural chemicals.
Used in Dye Production:
5-Bromo-2-methylbenzoyl chloride is employed as a starting material in the synthesis of dyes. Its unique structure allows for the development of dyes with specific properties, such as color intensity and stability, which are essential for various applications in textiles, printing, and other industries.
Used in Fine Chemicals Synthesis:
As a versatile intermediate, 5-Bromo-2-methylbenzoyl chloride is used in the synthesis of a wide range of fine chemicals. Its ability to participate in various organic transformations enables the production of specialty chemicals for use in research, analytical chemistry, and other high-value applications.

InChI:InChI=1/C8H6BrClO/c1-5-2-3-6(9)4-7(5)8(10)11/h2-4H,1H3

Upstream product

• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 79669-49-1 5-bromo-2-methylbenzoic acid 

Downstream Products

• 333361-13-0 5-bromo-2-methyl-4'-methoxybenzophenone 
• 1610954-87-4 (3aS,5S,6R,6aS)-5-((S)-(3-(4-chlorobenzyl)-4-methylphenyl)-(hydroxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 
• 1357258-91-3 C₃₄H₄₀N₄O₃ 
• 1357258-89-9 C₁₂H₁₆BrNO 
• 1221506-24-6 (5-bromo-2-methylphenyl)(4-ethoxyphenyl)methanone 
• 1132832-75-7 (5-bromo-2-methylphenyl)[5-(p-fluorophenyl)thiophene-2-yl]methanone 
• 854633-21-9 5-bromo-2-methylbenzamide 
• 1194769-56-6 5-bromo-2-methylbenzohydrazide 

Relevant academic research and scientific papers

Synthesis of Novel Nitrogen-Containing Heterocycle Bromophenols and Their Interaction with Keap1 Protein by Molecular Docking

We previously reported 5,2’-dibromo-2,4’,5’-trihydroxydiphenylmethanoe (LM49), a bromophenol analogue that shows strong protection from oxidative stress injury owing to its superior anti-inflammatory, antioxidant, and anti-apoptotic properties. A series of novel nitrogen-containing heterocycle bromophenols were herein synthesized by introducing substituted piperidine, piperazine, and imidazole to modify 2-position of the lead compound LM49. By further evaluating their cytoprotective activity against H2O2 induced injury in EA.hy926 cells, 14 target bromophenols showed moderate-to-potent activity with EC50 values in the range of 0.9–6.3 μM, which were stronger than that of quercetin (EC50: 18.0 μM), a positive reference compound. Of these, the most potent compound 22b is a piperazine bromophenol with an EC50 value of 0.9 μM equivalent to the LM49. Molecular docking studies were subsequently performed to deduce the affinity and binding mode of derived halophenols toward the Keap1 Kelch domain, the docking results exhibited that the small molecule 22b is well accommodated by the bound region of Keap1-Kelch and Nrf2 through stable hydrogen bonds and hydrophobic interaction, which contributed to the enhancement of affinity and stability between the ligand and receptor. The above facts suggest that 22b is a promising pharmacological candidate for further cardiovascular drug development. Moreover, the targeting Keap1-Nrf2 protein-protein interaction may be an emerging strategy for halophenols to selectively and effectively activate Nrf2 triggering downstream protective genes defending against injury.

Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy

Nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) catalyzes the hydrolysis of extracellular nucleotides. It is expressed by immune cells and some carcinomas,e.g.of kidney and colon. Together with ecto-5′-nucleotidase (CD73), NPP3 produces immunosuppres

PEST CONTROL METHOD

PROBLEM TO BE SOLVED: To provide a method for controlling pests. SOLUTION: A compound represented by formula (I), or an N oxide thereof or salts thereof can control pests. [In formula (I), Q is a group represented by Q1 or the like (a bullet symbol is a binding site to a benzene ring), E is a C1-C6 chain hydrocarbon group or the like, R1 is a C1-C3 chain hydrocarbon group or the like, n is 0, 1, 2 or 3, where if n is 2 or 3, a plurality of R2 may be the same or different, R2 is a C1-C3 chain hydrocarbon group or the like]. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

N-Heterocyclic Carbene Catalyzed Photoenolization/Diels–Alder Reaction of Acid Fluorides

The combination of light activation and N-heterocyclic carbene (NHC) organocatalysis has enabled the use of acid fluorides as substrates in a UVA-light-mediated photochemical transformation previously observed only with aromatic aldehydes and ketones. Stoichiometric studies and TD-DFT calculations support a mechanism involving the photoactivation of an ortho-toluoyl azolium intermediate, which exhibits “ketone-like” photochemical reactivity under UVA irradiation. Using this photo-NHC catalysis approach, a novel photoenolization/Diels–Alder (PEDA) process was developed that leads to diverse isochroman-1-one derivatives.

GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF

Provided are a glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

Glucopyranosyl derivative and its use in medicine (by machine translation)

The invention relates to a as sodium-dependent glucose transporter (SGLTs) inhibitors of the glucopyranosyl derivative, containing the pharmaceutical composition and its use in medicine, in particular of formula (I) indicated by the glucopyranosyl derivative or its pharmaceutically acceptable salt or all of its stereoisomers, or containing the pharmaceutical composition and said derivative and pharmaceutical composition for the preparation of a medicine for treating diabetes and diabetes related diseases of the use. (by machine translation)

Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) Inhibitor restricted to the intestinal lumen, for the treatment of diabetes

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodiumdependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF

C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of th

Iron-Catalyzed, Fluoroamide-Directed C-H Fluorination

This communication describes a mild, amide-directed fluorination of benzylic, allylic, and unactivated C-H bonds mediated by iron. Upon exposure to a catalytic amount of iron(II) triflate (Fe(OTf)2), N-fluoro-2-methylbenzamides undergo chemoselective fluorine transfer to provide the corresponding fluorides in high yield. The reaction demonstrates broad substrate scope and functional group tolerance without the use of any noble metal additives. Mechanistic and computational experiments suggest that the reaction proceeds through short-lived radical intermediates with F-transfer mediated directly by iron.

DIMETHYLBENZOIC ACID COMPOUNDS

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.